Assessing safety at the end of clinical trials using system organ classes: A case and comparative study.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1278, doi. 10.1002/pst.2148
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2021 AND VI 20 AND IP 6
Results: 25
1
2
Identifying treatment effects using trimmed means when data are missing not at random.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1265, doi. 10.1002/pst.2147
- By:
- Publication type:
- Article
3
A mixed effects model for analyzing area under the curve of longitudinally measured biomarkers with missing data.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1249, doi. 10.1002/pst.2146
- By:
- Publication type:
- Article
4
Comments on "Equal‐tailed confidence intervals for comparison of rates".
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1288, doi. 10.1002/pst.2145
- Publication type:
- Article
5
Author's reply to the letter to the editor by Yongqiang Tang: Comments on "Equal‐tailed confidence intervals for comparison of rates".
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1293, doi. 10.1002/pst.2144
- Publication type:
- Article
6
The individual‐level surrogate threshold effect in a causal‐inference setting with normally distributed endpoints.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1216, doi. 10.1002/pst.2141
- By:
- Publication type:
- Article
7
Bayesian single‐arm phase II trial designs with time‐to‐event endpoints.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1235, doi. 10.1002/pst.2143
- By:
- Publication type:
- Article
8
Mitigation of the convergence issues associated with semi‐replicated bioequivalence data.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1232, doi. 10.1002/pst.2142
- Publication type:
- Article
9
Dose intra‐subject escalation to an event (DIETE): A new method for phase 1 dose‐finding utilizing systematic intra‐subject dose escalation with application to T‐cell engagers.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1200, doi. 10.1002/pst.2140
- By:
- Publication type:
- Article
10
The use of local and nonlocal priors in Bayesian test‐based monitoring for single‐arm phase II clinical trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1183, doi. 10.1002/pst.2139
- By:
- Publication type:
- Article
11
Selection bias, investment decisions and treatment effect distributions.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1168, doi. 10.1002/pst.2132
- By:
- Publication type:
- Article
12
Joint confidence region estimation on predictive values.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1147, doi. 10.1002/pst.2131
- By:
- Publication type:
- Article
13
Estimating and comparing adverse event probabilities in the presence of varying follow‐up times and competing events.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1125, doi. 10.1002/pst.2130
- By:
- Publication type:
- Article
14
The detailed clinical objectives approach to designing clinical trials and choosing estimands.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1112, doi. 10.1002/pst.2129
- By:
- Publication type:
- Article
15
Conditional assurance: the answer to the questions that should be asked within drug development.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1102, doi. 10.1002/pst.2128
- By:
- Publication type:
- Article
16
Using marginal structural models to analyze the impact of subsequent therapy on the treatment effect in survival data: Simulations and clinical trial examples.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1088, doi. 10.1002/pst.2127
- By:
- Publication type:
- Article
17
Bayes shrinkage estimator for consistency assessment of treatment effects in multi‐regional clinical trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1074, doi. 10.1002/pst.2126
- By:
- Publication type:
- Article
18
A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detection.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1061, doi. 10.1002/pst.2125
- By:
- Publication type:
- Article
19
Inverse probability of censoring weighting for visual predictive checks of time‐to‐event models with time‐varying covariates.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1051, doi. 10.1002/pst.2124
- By:
- Publication type:
- Article
20
The use of external controls: To what extent can it currently be recommended?
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1002, doi. 10.1002/pst.2120
- By:
- Publication type:
- Article
21
Improving sample size recalculation in adaptive clinical trials by resampling.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1035, doi. 10.1002/pst.2122
- By:
- Publication type:
- Article
22
Incorporating historical information to improve phase I clinical trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 1017, doi. 10.1002/pst.2121
- By:
- Publication type:
- Article
23
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 990, doi. 10.1002/pst.2119
- By:
- Publication type:
- Article
24
Synergy evaluation of non‐normalizable dose–response data: Generalization of combination index for the linear effect of drugs.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 982, doi. 10.1002/pst.2118
- By:
- Publication type:
- Article
25
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 6, p. 979, doi. 10.1002/pst.2038
- Publication type:
- Article